secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001654954-23-012433
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics gets Nasdaq extension to March 25, 2024 for $1 bid price rule
--------------------------------------------------------------------------------

- Nasdaq granted extension through March 25, 2024 to regain compliance with $1.00 minimum bid price (Rule 5550(a)(2)).
- Original compliance period ended Sept. 25, 2023; extension provides six additional months.
- If bid price closes at $1.00+ for ten consecutive days, Nasdaq will confirm compliance.
- If not compliant by March 25, 2024, Nasdaq will issue delisting notice; company may appeal.
- Company evaluating options including reverse stock split; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423012433/0001654954-23-012433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423012433/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-012433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer